Medical Information
In order to provide you with relevant and meaningful content we need to know more about you.
Please choose the category that best describes you.
This content is intended for U.S. Healthcare Professionals. Would you like to proceed?
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
Butorphanol Tartrate Injection is indicated
Use the lowest effective dosage for the shortest duration consistent with individual patient...
Butorphanol tartrate injection is a Schedule IV controlled substance. As an opioid, butorphanol tartrate exposes users to the...
A total of 1658 patients were studied in premarketing clinical trials of Butorphanol Tartrate Injection. In nearly all...
Butorphanol Tartrate Injection contains butorphanol, a Schedule IV controlled substance.
Acute overdose with butorphanol tartrate can be manifested by respiratory depression, somnolence progressing to stupor or coma,...
Butorphanol tartrate is a synthetically derived opioid agonist-antagonist analgesic of the phenanthrene series. The chemical name is (-)-17-(cyclobutylmethyl) morphinan-3, 14-diol D-(-)- tartrate (1:1) (salt)....
Butorphanol is a partial opioid agonist at the mu opioid receptor and a full agonist at the kappa opioid receptor. The...
Butorphanol Tartrate Injection, USP is supplied as follows:
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this product, click the link below to submit your information: Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer product, please call Pfizer Medical Information at (800) 438-1985.
